AstraZeneca releases extensive real-world evidence supporting SGLT-2 inhibitors

London-based AstraZeneca (LSE: AZN) has released a new analysis of data from its real-world evidence based CVD-REAL study evaluating the outcomes for type-2 diabetes patients undergoing treatment with SGLT-2 inhibitors.

The study, which compares SGLT-2 inhibitors such as AstraZeneca’s own Farxiga (dapagliflozin) with other glucose-lowering medicines, looks at data from more than 400,000 patients across six countries.

Results showed that treatment with an SGLT-2 inhibitor was associated with a 49% lower risk of death, 36% lower risk of hospitalization for heart failure, 19% lower risk of heart attack and 32% lower risk of stroke.